WO2023247738 - COMPOSITIONS AND METHODS FOR INHIBITING TRANSMEMBRANE SERINE PROTEASE 6 (TMPRSS6) EXPRESSION

National phase entry is expected:
Publication Number WO/2023/247738
Publication Date 28.12.2023
International Application No. PCT/EP2023/067070
International Filing Date 23.06.2023
Title **
[English] COMPOSITIONS AND METHODS FOR INHIBITING TRANSMEMBRANE SERINE PROTEASE 6 (TMPRSS6) EXPRESSION
[French] COMPOSITIONS ET PROCÉDÉS POUR INHIBER L'EXPRESSION DE LA SÉRINE PROTÉASE TRANSMEMBRANAIRE 6 (TMPRSS6)
Applicants **
NOVO NORDISK A/S Novo Allé 1 2880 Bagsværd, DK
DICERNA PHARMACEUTICALS INC. 75 Hayden Avenue Lexington, Massachusetts 02421, US
Inventors
BLOIS, Anna, Linda 75 Hayden Avenue Lexington, Massachusetts 02421, US
PRIEST, Christina Marie 75 Hayden Avenue Lexington, Massachusetts 02421, US
PARK, Jihye 75 Hayden Avenue Lexington, Massachusetts 02421, US
DUDEK, Henryk 75 Hayden Avenue Lexington, Massachusetts 02421, US
Priority Data
63/355,210   24.06.2022   US
22209113.4   23.11.2022   EP
front page image
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
*
International Searching Authority
*
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing2181
EPO Filing, Examination7479
Japan Filing592
South Korea Filing608
USA Filing, Examination4735
MasterCard Visa

Total: 15595

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression. 5[French] L'invention concerne des oligonucléotides qui inhibent l'expression de la TMPRSS6. L'invention concerne des compositions les comprenant et leurs utilisations, en particulier des utilisations liées au traitement de maladies, de troubles et/ou d'affections associés à l'expression de la TMPRSS6 .
An error has occurred. This application may no longer respond until reloaded. Reload 🗙